Mesoblast Limited (NASDAQ: MESO) and Fibrocell Science (NASDAQ:FCSC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.
This table compares Mesoblast Limited and Fibrocell Science’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of recent ratings and price targets for Mesoblast Limited and Fibrocell Science, as reported by MarketBeat.com.
||Strong Buy Ratings
Mesoblast Limited currently has a consensus price target of $14.25, indicating a potential upside of 97.10%. Fibrocell Science has a consensus price target of $5.53, indicating a potential upside of 118.71%. Given Fibrocell Science’s stronger consensus rating and higher possible upside, analysts clearly believe Fibrocell Science is more favorable than Mesoblast Limited.
Institutional and Insider Ownership
3.0% of Mesoblast Limited shares are owned by institutional investors. Comparatively, 54.7% of Fibrocell Science shares are owned by institutional investors. 2.1% of Fibrocell Science shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Mesoblast Limited and Fibrocell Science’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
Fibrocell Science has higher revenue, but lower earnings than Mesoblast Limited. Mesoblast Limited is trading at a lower price-to-earnings ratio than Fibrocell Science, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Mesoblast Limited has a beta of 2.74, suggesting that its share price is 174% more volatile than the S&P 500. Comparatively, Fibrocell Science has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.
Mesoblast Limited beats Fibrocell Science on 7 of the 13 factors compared between the two stocks.
About Mesoblast Limited
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
About Fibrocell Science
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.